InvestorsHub Logo

tractor4sale

08/18/22 2:11 PM

#52867 RE: BigBadWolf #52864

Now take the time to describe what an IND# is for? Then more importantly how does it pertain to the “Right to Try” Law?

Therapeutic Solutions International announced today granting of Emergency IND # 28685 and a "May Proceed Notification" from the Food and Drug Administration (FDA) for the treatment of advanced COVID-19 ARDS outside of the currently ongoing Double Blind Placebo Controlled Phase III clinical trial for the same indication. The Company previously announced treatment of 15 "no option patients" under both "eIND" and "Right to Try" Law1

tractor4sale

08/18/22 2:18 PM

#52868 RE: BigBadWolf #52864

The awakening begins today! Emphasis on “who are UNABLE TO PARTICIPATE IN A CLINICAL TRIAL to access certain unapproved treatments”…

“The Right to Try Act, or the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act, was signed into law May 30, 2018. This law is another way for patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial to access certain unapproved treatments”…

tractor4sale

08/18/22 3:21 PM

#52871 RE: BigBadWolf #52864

Well there it is! The TSOI EMERGENCY IND # 28685 with the “MAY PROCEED NOTIFICATION” which gives TSOI the RIGHT to treat patients with “NO OTHER OPTIONS” and “who are UNABLE TO PARTICIPATE IN A CLINICAL TRIAL to access certain unapproved treatments” which is granted by the “RIGHT TO TRY” LAW… Nobody can be confused now! There is nothing left to be said! NOTHING NEEDS TO BE ON THE CLINICAL TRIALS SITE because the patients aren’t participating in a clinical trial! Everyone knows that…

Therapeutic Solutions International announced today granting of Emergency IND # 28685 and a "May Proceed Notification" from the Food and Drug Administration (FDA) for the treatment of advanced COVID-19 ARDS outside of the currently ongoing Double Blind Placebo Controlled Phase III clinical trial for the same indication. The Company previously announced treatment of 15 "no option patients" under both "eIND" and "Right to Try" Law1